Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 5

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
Last September, the Democratic-controlled U.S. House Oversight and Reform Committee released a 45-page report focused on Celgene and Bristol Myers Squibb’s (BMS’s) nearly two dozen price increases on Revlimid from 2005, when Celgene bought the drug, through 2019. It was
Read More »

More Than a Third of State Lawmakers Accept Pharma Campaign Contributions, Analysis Shows

More than one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution during the past two years, an analysis of campaign finance records by news organization STAT found.
In the last two years, over one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution, news organization STAT reports.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 4

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
The impact on health care providers of being unable to access Revlimid at the 340B price is significant, financially and in terms of patient care, according to numerous health system representatives that 340B Report interviewed. (All current and former health
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 3

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
The myeloma drugs Revlimid and Pomalyst are analogues of Thalomid, aka thalidomide—a drug that still haunts those who remember the late 1950s and early 1960s. Marketed mainly in Europe as an over the counter sedative and morning sickness medicine for
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 2

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
Editor’s note: We invited Bristol Myers Squibb (BMS), which bought Celgene in November 2019, to respond to allegations of illegal or questionable conduct by Celgene with respect to its myeloma drugs and the 340B program. BMS said: “Bristol Myers Squibb
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 1

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 1 of 6—Why Can So Few 340B Hospitals Buy and Dispense the Highly Profitable Cancer Drug Revlimid?

Possibly more than a thousand hospitals in the 340B drug discount program can’t buy or dispense Revlimid, a widely-used oral drug to

Read More »

Much Cheaper PrEP Drugs Could Mean Financial Upheaval for 340B Covered Entities

Broad availability of low-cost generic pre-exposure prophylaxis drugs could significantly reduce 340B covered entities' revenues on billings for PrEP. | Shutterstock
While an important drug’s introduction into the generic market is often celebrated by both providers and patients, generic pre-exposure prophylaxis drugs (PrEP) for patients at risk of contracting HIV could prove a financial disaster for some 340B covered entities.
Read More »

United Therapeutics Delays its 340B Claims Data Upload Requirement

United Therapeutics pushed back a contract pharmacy claims data sharing requirement for 340B covered entities from today to Sept. 1.
United Therapeutics is holding off on requiring 340B covered entities to turn over their contract pharmacy claims data in order to get 340B pricing on drugs shipped to those pharmacies. The policy was supposed to take effect today. It will
Read More »

Takeda Pharmacy Partner Forcing 340B Pricing Opt-in/Opt-out Choice on Entities

Takeda business partner Foundation Care is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing “on eligible product purchases,” as a condition for obtaining a Takeda leukemia drug | Shutterstock
Drug manufacturer Takeda’s designated specialty pharmacy and distributor for its leukemia drug Iclusig is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing on purchases, as a condition for obtaining
Read More »